Implantable gestrinone

Phase 3Small molecule

BBio Meds Pharmaceutica Ltda

Implantable gestrinone is one of 48 small molecule programs targeting Endometriosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisRecruiting

EndometriosisPhase 3

Recruiting

Competition

Competitive Landscape

60 competitors in Endometriosis

#DrugCompanyPhaseTrials

Danocrine

Sanofi

Approved

5 2

Bayer Aspirin

Bayer

Approved

2 3

Orilissa

AbbVie

Phase 3

16 4

IC-Green

PProvepharm SAS

Approved

4 5

Estrace

Novo Nordisk

Approved

—6

Ketalar

AAultman Health Foundation

Approved

2 7

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Approved

1 8

Zocor

OOrganon and Co

Approved

1 9

Trelstar

OOncoVerity, Inc.

Approved

1 10

Implanon

OOrganon and Co

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometriosis1 trial

Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis

Recruiting·BBio Meds Pharmaceutica Ltda·Phase 4·NCT06543550·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Implantable gestrinone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Implantable gestrinone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Implantable gestrinone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bio Meds Pharmaceutica Ltda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBio Meds Pharmaceutica Ltda

Implantable gestrinone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News